Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...
Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...
12d
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
GSK (GSK) and Pfizer (PFE) vaccines for respiratory syncytial virus, or RSV, will carry warnings that they can increase the risk of developing a rare neurological disorder, Reuters writes.
According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
If you or someone you care about might be at risk for RSV, consult your healthcare provider. — JT Editor's Note: This health service message is brought to you by GSK. It is produced by the ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback